2025.6.10
Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
The forecasts, strategies and other items that are not historical facts contained in this document are based on information available to the Group at the time the document was created, and the Group does not guarantee the accuracy of this information. These may differ significantly from the forecasts due to changes in the economic and business environments, etc.
Performance Highlights
Performance Highlights - Consolidated Financial Results For The Nine Months Ended April 30, 2025 Segment Highlights
Notes | |
Consolidated Financial results | R&D expenses rose by 36%, and advertising expenses increased by 16%, underscoring continued strategic investment. Both BtoB and BtoC segments maintained profitability, reflecting the strength of core operations. Upfront advertising investment due to strong sales led to a temporary Q3 deficit; full-year profitability remains on track. |
BtoB Business | Channel expansion efforts continued. "Newmo" is set to roll out to 10,000 drugstores nationwide. Proprietary functional beverages secured shelf space in major supermarket chains, signaling steady market penetration. |
BtoC Business | Trend reversal gained further momentum, with customer acquisition accelerating- driven primarily by new pharmaceutical products. The number of regular customers increased by 87,000 compared to the previous fiscal year-end. Despite quarterly advertising expenses reaching ¥10.8 billion, the second-highest level on record, the segment remained profitable on a cumulative basis through the third quarter. |
Biomedical Business | The final-year contract under the Japan Agency for Medical Research and Development/AMED's program for next-generation drug discovery technologies has been signed. Key technologies have been consolidated into an integrated platform for next-generation antibody development, with validation studies targeting pharmaceutical antigens currently in progress. |
Mid-Term Business Plan 2026 - New Value Creation 1K | Over 80,000 visitors attended the company's booth within the first month of EXPO 2025. Innovative fiber products containing ovoveil, designed with sustainability and human well-being in mind, were launched globally for the first time through 7-Eleven, garnering widespread attention. |
Performance Highlights - Consolidated Financial Results For The Nine Months Ended April 30, 2025 Consolidated Sales (Cumulative)
(Unit：Million Yen)
FY2024 Q3 | FY2025 Q3 | YoY Changes | |
BtoB Business | 6,507 | 5,834 | ▲10.3％ |
BtoC Business | 40,418 | 40,728 | +0.8% |
Biomedical Business | 231 | 239 | +3.6% |
Others | 13 | 14 | +10.0% |
Total | 47,171 | 46,817 | ▲0.8% |
Performance Highlights - Consolidated Financial Results For The Nine Months Ended April 30, 2025 Consolidated Operational Profit (Cumulative)
(Unit：Million Yen)
FY2024 Q3 | FY2025 Q3 | YoY Changes | |
BtoB Business | 1,313 | 882 | ▲32.8％ |
BtoC Business | 3,331 | 591 | ▲82.2％ |
Biomedical Business | ▲315 | ▲274 | ＋41 |
Others | ▲13 | ▲5 | +8 |
Adjustments （Corporate expenses etc） | ▲1,050 | ▲1,411 | ▲360 |
Total | 3,266 | ▲217 | ▲3,483 |